EXO-OC Technical Review and Commercialisation Pathway

Summary by 6ix AI

Inoviq Ltd has announced the completion of an independent technical review of its EXO-OC ovarian cancer test, confirming its biological relevance and outlining a commercialisation pathway for the test in the US. The review identified pre-analytical sample collection issues as the main source of variability in a previous study and recommended a staged program for assay optimisation and validation. The company aims to advance EXO-OC towards commercialisation as a Laboratory Developed Test, targeting completion of laboratory validation by the first half of a future year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries